Article
Oncology
Alexandra Leary, Ana Oaknin, Jose Manuel Trigo, Victor Moreno, Jean-Pierre Delord, Valentina Boni, Irene Brana, Cristian Fernandez, Carmen Kahatt, Antonio Nieto, Martin Cullell-Young, Ali Zeaiter, Vivek Subbiah
Summary: Lurbinectedin is an approved drug for the treatment of metastatic small cell lung cancer. This study analyzes safety data from various solid tumors treated with Lurbinectedin, and confirms its manageable safety profile in patients with advanced solid tumors.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Zuzana Bielcikova, Jan Stursa, Ludmila Krizova, Lanfeng Dong, Jan Spacek, Stanislav Hlousek, Michal Vocka, Katerina Rohlenova, Olga Bartosova, Vladimir Cerny, Tomas Padrta, Michal Pesta, Pavel Michalek, Sona Stemberkova Hubackova, Katarina Kolostova, Eliska Pospisilova, Vladimir Bobek, Peter Klezl, Renata Zobalova, Berwini Endaya, Jakub Rohlena, Lubos Petruzelka, Lukas Werner, Jiri Neuzil
Summary: MitoTam, a mitochondria-targeted anti-cancer agent, was tested in a phase I/Ib trial with 75 metastatic cancer patients. The study found that MitoTam showed high efficacy against renal cell carcinoma.
Article
Oncology
Jacob S. Thomas, Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek K. Pinski, Everardo Cobos, David R. Gandara, Heinz J. Lenz, Min H. Kang, C. Patrick Reynolds, Edward M. Newman
Summary: The study aimed to investigate the tolerability, efficacy, and pharmacokinetics of intravenous lipid emulsion fenretinide in patients with advanced solid tumors. The results showed that the formulation had a manageable safety profile and achieved higher plasma steady-state concentrations of the active metabolite compared to previous capsule formulations.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2021)
Review
Oncology
Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, Sara M. Tolaney
Summary: Improvements in the design of antibody-drug conjugates (ADCs) have reshaped the treatment of advanced-stage solid tumours, but toxicities of ADCs are still a concern. Ongoing efforts are being made to enhance the safety of ADCs, including optimizing dose and treatment schedule, modifying ADC components, identifying predictive biomarkers for toxicities, and developing innovative diagnostic tools.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Oncology
Patrick Schoeffski, Ahmad Awada, Anne-Marie de la Bigne, Zakia Felloussi, Mike Burbridge, Frederique Cantero, Riccardo Colombo, Sara Maruzzelli, Katia Ammattatelli, Maja de Jonge, Philippe Aftimos, Herlinde Dumez, Stefan Sleijfer
Summary: S81694 can be safely administered as a single agent in adults with solid tumors at a dose of up to 135 mg/m(2)/week on days 1,8,15 of a 28-day cycle, without reaching the MTD.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Gary Edward Richardson, Raed Al-Rajabi, Dipesh Uprety, Anis Hamid, Stephen K. Williamson, Joaquina Baranda, Hirva Mamdani, Ya-Li Lee, Li Li, Xingli Wang, Xunwei Dong
Summary: FN-1501, a novel intravenous FLT3 inhibitor, has shown potential efficacy and safety for patients with advanced solid tumors. The maximum tolerated dose (MTD) of FN-1501 was determined to be 170 mg, demonstrating reasonable safety, tolerability, and preliminary activity against solid tumors.
Article
Medicine, General & Internal
Anita K. Patel, Jiaxiang Gai, Eduardo Trujillo-Rivera, Farhana Faruqe, Dongkyu Kim, James E. Bost, Murray M. Pollack
Summary: The adoption of multimodal pain regimens that incorporate nonopioid analgesic medications can prevent serious opioid-related adverse effects in children. This study found that IV acetaminophen administered prior to IV opioids was associated with a 15.5% reduction in IV opioid duration in pediatric inpatients.
Article
Medicine, General & Internal
Daniel D. Karp, D. Ross Camidge, Jeffery R. Infante, Tyler D. Ames, Matthew R. Price, Jose Jimeno, Alan H. Bryce
Summary: PT-112, the first pyrophosphate-platinum conjugate, shows immunogenic cell death and recruitment of tumour-infiltrating lymphocytes in experimental models. This study investigates the safety and efficacy of PT-112 monotherapy in heavily pre-treated patients with advanced solid tumours. PT-112 demonstrates prolonged responses in thymoma and lung cancer, and improves radiographic and serum marker outcomes in prostate cancer.
Article
Pharmacology & Pharmacy
Xiaoqing Li, Yunhai Bo, Han Yin, Xiaohong Liu, Xu Li, Fen Yang
Summary: TQ-B3203 is a novel topoisomerase I inhibitor being developed for the treatment of advanced solid tumors. A population pharmacokinetic model was established to identify key factors and their influence on pharmacokinetic parameters and guide individualized administration. Covariates, such as direct bilirubin (DBIL) and body mass index (BMI), were found to significantly affect clearance and distribution volume.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Patrick Schoffski, Jean -Pascal Machiels, Sylvie Rottey, Behbood Sadrolhefazi, Hanny Musa, Kristell Marzin, Ahmad Awada
Summary: BI 894999, a novel oral BET inhibitor, has shown potent antitumour activity in preclinical studies.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Rosario Mazzola, Francesco Cuccia, Alessandro Bertani, Slavisa Tubin, Pier Giulio Conaldi, Stefanie Corradini, Maria Tolia, Markus Guba, Filippo Alongi
Summary: Radiotherapy in cancer patients with prior organ transplants poses challenges due to potential effects on immunosuppressive therapy and organ tolerance. This systematic review aims to assess the safety and efficacy of radiotherapy in these patients, focusing on modern treatment techniques.
Article
Health Care Sciences & Services
Raja Pramanik, Sandeep Agarwala, Vishnubhatla Sreenivas, Deepa Dhawan, Sameer Bakhshi
Summary: This study compared the health-related quality of life (HRQoL) between pediatric solid tumor patients randomized to receive metronomic chemotherapy or placebo. The results showed no significant difference in HRQoL between the two treatment arms.
BMJ SUPPORTIVE & PALLIATIVE CARE
(2023)
Article
Oncology
Yi-Long Wu, Ying Cheng, Huajun Chen, Haiyan Tu, Chongrui Xu, Zhen Wang, Ying Liu, Ying Xin, Haizhou Lou, Wei Wang, Kevin Chin, Dandan Li, Di Zhao, Yanfei Gao, Wenping Xu, Hongming Pan
Summary: This study evaluated the safety and pharmacokinetics of avelumab in Chinese patients with advanced solid tumors. The results were consistent with previous global studies, showing some therapeutic effects in Chinese patients.
Article
Multidisciplinary Sciences
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis
Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
David M. Loeb, Ji Won Lee, Daniel A. Morgenstern, Yvan Samson, Anne Uyttebroeck, Chuhl Joo Lyu, An Van Damme, Karsten Nysom, Margaret E. Macy, Alexandra P. Zorzi, Julia Xiong, Petra Pollert, Ingrid Joerg, Yulia Vugmeyster, Mary Ruisi, Hyoung Jin Kang
Summary: In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)